Prodrugs of a 1-Hydroxy-2-oxopiperidin-3-yl Phosphonate Enolase Inhibitor for the Treatment of ENO1-Deleted Cancers

[Image: see text] Cancers harboring homozygous deletion of the glycolytic enzyme enolase 1 (ENO1) are selectively vulnerable to inhibition of the paralogous isoform, enolase 2 (ENO2). A previous work described the sustained tumor regression activities of a substrate-competitive phosphonate inhibitor...

Descripción completa

Detalles Bibliográficos
Autores principales: Yan, Victoria C., Pham, Cong-Dat, Ballato, Elliot S., Yang, Kristine L., Arthur, Kenisha, Khadka, Sunada, Barekatain, Yasaman, Shrestha, Prakriti, Tran, Theresa, Poral, Anton H., Washington, Mykia, Raghavan, Sudhir, Czako, Barbara, Pisaneschi, Federica, Lin, Yu-Hsi, Satani, Nikunj, Hammoudi, Naima, Ackroyd, Jeffrey J., Georgiou, Dimitra K., Millward, Steven W., Muller, Florian L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Chemical Society 2022
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9620261/
https://www.ncbi.nlm.nih.gov/pubmed/36251833
http://dx.doi.org/10.1021/acs.jmedchem.2c01039

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9620261/
https://www.ncbi.nlm.nih.gov/pubmed/36251833
http://dx.doi.org/10.1021/acs.jmedchem.2c01039

Ejemplares similares